Mutaflor (Escherichia Coli Strain Nissle 1917)

Escherichia coli Nissle 1917, the active ingredient in Mutaflor, is a probiotic presented as an oral formulation for oral administration. It belongs to the gastrointestinal microbiota modulator class and is used to support intestinal balance and to maintain remission in patients with ulcerative colitis.

GNH USA supplies Mutaflor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet the needs of healthcare providers across multiple regions.

Mutaflor, a probiotic targeting the gastrointestinal microbiota, is indicated for the following condition:

- Ulcerative colitis (maintenance of remission): helps sustain a disease‑free state in patients who have achieved remission.

Adverse reactions reported with Mutaflor are generally mild and reversible.

Common Side Effects: - Abdominal discomfort: mild pain or cramping. - Flatulence: increased gas production. - Nausea: occasional feeling of queasiness. - Diarrhoea: loose stools. - Headache: transient mild headache. - Transient fever: low‑grade temperature rise.

Serious or Rare Side Effects: - Bacteraemia: presence of bacteria in the bloodstream. - Sepsis: systemic infection requiring urgent care. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypersensitivity: urticaria or angioedema. - Systemic infection in immunocompromised patients. - Persistent gastrointestinal infection.

Before prescribing Mutaflor, clinicians should consider the following precautions: - Immunocompromised patients: evaluate risk of systemic infection. - Recent antibiotic therapy: assess potential reduction in probiotic viability. - Underlying severe gastrointestinal disease: monitor for complications. - Pregnancy and lactation: safety data are limited; use only if clearly needed. - Pediatric use: limited data; prescribe with caution. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Mutaflor may interact with other agents that affect gut flora or immune function.

Major Interactions (Avoid): - Broad‑spectrum antibiotics: may eradicate the probiotic strain and diminish efficacy. - Immunosuppressive biologics: increase risk of systemic infection.

Moderate Interactions (Monitor Closely): - Other probiotic products: potential competition for colonisation. - Antidiarrhoeal agents (e.g., loperamide): may alter transit time and affect bacterial survival. - Antifungal medications: possible indirect effects on gut microbiota balance. - Vaccines containing live attenuated organisms: consider timing to avoid interference.